Sea Mild Biotechnology Balance Sheet Health
Financial Health criteria checks 5/6
Sea Mild Biotechnology has a total shareholder equity of NT$70.4M and total debt of NT$25.0M, which brings its debt-to-equity ratio to 35.5%. Its total assets and total liabilities are NT$190.4M and NT$120.0M respectively. Sea Mild Biotechnology's EBIT is NT$4.8M making its interest coverage ratio 7.2. It has cash and short-term investments of NT$46.6M.
Key information
35.5%
Debt to equity ratio
NT$25.00m
Debt
Interest coverage ratio | 7.2x |
Cash | NT$46.63m |
Equity | NT$70.41m |
Total liabilities | NT$119.96m |
Total assets | NT$190.36m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 7516's short term assets (NT$150.8M) exceed its short term liabilities (NT$113.6M).
Long Term Liabilities: 7516's short term assets (NT$150.8M) exceed its long term liabilities (NT$6.3M).
Debt to Equity History and Analysis
Debt Level: 7516 has more cash than its total debt.
Reducing Debt: 7516's debt to equity ratio has increased from 25.2% to 35.5% over the past 5 years.
Debt Coverage: 7516's debt is well covered by operating cash flow (35.4%).
Interest Coverage: 7516's interest payments on its debt are well covered by EBIT (7.2x coverage).